No abstract

Introduction Noninvasive ventilation is a safe and eff ective method to treat acute respiratory failure, minimizing the respiratory workload and oxygenation. Few studies compare the effi cacy of diff erent types of noninvasive ventilation interfaces and their adaptation. Objective To identify the most frequently noninvasive ventilation interfaces used and eventual problems related to their adaptation in critically ill patients. Methods We conducted an observational study, with patients older than 18 years old admitted to the intensive care and step-down units of the Albert Einstein Jewish Hospital that used noninvasive ventilation. We collected data such as reason to use noninvasive ventilation, interface used, scheme of noninvasive ventilation used (continuously, periods or nocturnal use), adaptation, and reasons for nonadaptation. Results We evaluated 245 patients with a median age of 82 years (range of 20 to 107 years). Acute respiratory failure was the most frequent cause of noninvasive ventilation used (71.3%), followed by pulmonary expansion (10.24%), after mechanical ventilation weaning (6.14%) and sleep obstructive apnea (8.6%). The most frequently used interface was total face masks (74.7%), followed by facial masks in 24.5% of the patients, and 0.8% used performax masks. The use of noninvasive ventilation for periods (82.4%) was the most common scheme of use, with 10.6% using it continuously and 6.9% during the nocturnal period only. Interface adaptation occurred in 76% of the patients; the 24% that did not adapt had their interface changed to improve adaptation afterwards. The total face mask had 75.5% of interface adaptation, the facial mask had 80% and no adaptation occurred in patients that used the performax mask. The face format was the most frequent cause of nonadaptation in 30.5% of the patients, followed by patient's related discomfort (28.8%), air leaking (27.7%), claustrophobia (18.6%), noncollaborative patient (10.1%), patient agitation (6.7%), facial trauma or lesion (1.7%), type of mask fi xation (1.7%), and 1.7% patients with other causes. Conclusion Acute respiratory failure was the most frequent reason for noninvasive ventilation use, with the total face mask being the most frequent interface used. The most common causes of interface nonadaptation were face format, patient-related discomfort and air leaking, showing improvement of adaptation after changing the interface used. P2 Exercise training reduces oxidative damage in skeletal muscle of septic rats

apolipoprotein ε4 (APOE4) status and years of education were added as intercept and/or slope effects in the mixed model as guided by exploratory analyses of the two outcomes. A time-dependent APCC covariate accounted for the hypothesized dependence of time to diagnosis on APCC decline. The model was fitted with the {JM} package from R v3.4.3 on 2047 subjects with at least two APCC measurements and who were cognitively unimpaired and less than 90 years old at inclusion. An internal validation was performed via predictive checks. RESULTS: The model captured the link between risk factors, early cognitive decline and time to diagnosis. The model-estimated longitudinal cognitive decline (population average and individual trajectories) and overall risk of developing MCI/AD symptoms provided a good fit to the data. As expected, the model estimated a higher risk of developing MCI/AD symptoms for older subjects and for APOE4 carriers. A significant association was observed between decline in APCC and the risk of developing MCI/AD symptoms. The joint model also adequately captured the individual dynamic risk of developing MCI/AD symptoms using personal longitudinal APCC data until a given observation time. CONCLUSIONS: This novel method provides a tool to dynamically estimate the individual risk of developing MCI/AD for cognitively unimpaired subjects who have longitudinal measures from sensitive neuropsychological tests.OBJECTIVES: Decision-makers need to understand long-term clinical outcomes to assess the cost-effectiveness of new treatments from a lifetime perspective. Given limited follow-up of clinical trials, our aim was to demonstrate that estimates from experts regarding long-term survival can be combined with empirical data from multiple clinical trials to provide more credible extrapolated survival curves. METHODS: A case study was performed using clinical trial (ELIANA) data with limited follow-up (1.5 years), which was combined with expert elicited survival rates from 2-5 years for patients with relapsed or refractory B-cell pediatric acute lymphoblastic leukemia treated with CTL019, a chimeric antigen receptor T-cell therapy. Additionally, a phase I CTL019 with no expert information was included. Elicited survival proportions (and uncertainty) from experts were transformed into discrete hazards for each interval. We incorporated expert information in a Bayesian hierarchical model with branches for experts and trials. Parameters defining survival for clinical trial data or expert opinion were estimated and combined to produce estimates of the 'true' parameters of the survival function. RESULTS: Standard survival models fit solely to the clinical trial data produced extrapolations that were extremely variable, despite minor differences in model fit statistics with 5-year estimates ranging from 0.0% to 52.4% (95% CrI: 0.0%, 84.2%). Incorporating expert information using a hierarchical model produced more consistent estimates with 5-year survival estimates of 53.2% (2.8%, 78.9%). Adding another clinical study wit...

No abstract

No abstract